Huawei CEO Ren Zhengfei laid out plans to bring more efficiencies to the organization. This included simplifying the reporting structure, cutting down on surplus staff, axing...Technologyread more
The bond market has entered a financial twilight zone, and at this point, there doesn't seem to be a smooth way out.Market Insiderread more
China has used both monetary and fiscal measures to lift economic activity as its trade war with the U.S. looks set to intensify in the coming months.China Economyread more
President Donald Trump said on Twitter he was postponing a scheduled meeting with Denmark's prime minister because of her lack of interest in discussing a possible sale of...World Politicsread more
"I think (rate cuts) will help, but whether they're going to be sufficient to counter the negative trade pressures and global growth slowdown and impact is debatable," one...Central Banksread more
Chinese overseas investment growth will likely slow or even decline in the next few years as risks around the world increase, according to new research by Moody's Investors...China Economyread more
The two countries want to smash the civil aerospace duopoly enjoyed by Airbus and Boeing.Aerospace & Defenseread more
Alibaba held a board meeting before its latest quarterly earnings release last week, during which the board decided to postpone the Hong Kong listing, Reuters reported.Technologyread more
Federal Reserve Chairman Jerome Powell is set to deliver his annual speech on Friday at the Jackson Hole, Wyoming symposium, where he's expected to provide more clarity on the...Asia Marketsread more
U.S. and Asian investors poured $3.7 billion into U.K. tech start-ups in the first seven months of 2019, research shows.Technologyread more
After Elon Musk touts Tesla solar on Twitter, Walmart sues the electric vehicle and clean energy company over store rooftop panels that ignited.Technologyread more
stock bounced back in midday trading Wednesday from lower-than-expected second quarter earnings after the company's management said its generic drug Advair is not being delayed by further FDA-required studies.
After shares of the drug-maker dropped as far as 8 percent in premarket trading, Mylan's CEO Heather Bresch clarified on a call with investors that delaying Advair's launch to 2018 was due to the Food and Drug Administration reorganizing and changing its priorities.
"We see the administration as the barrier, and not the science," Bresch said.
Mylan's second-quarter earnings report missed estimates in what Bresch called "a tough quarter," before adding more optimistically that the company is "managing for the long term." Bresch believes the poor quarterly result was not a "permanent hit" but rather "a deferred one."
The company reported total revenue of $2.96 billion and earnings per share of $1.10, missing estimates of $3.03 billion in revenues and EPS of $1.16, according to analysts surveyed by Thomson Reuters.
Mylan is coping with declining profitability and it adjusted annual earnings forecasts downward. An August 2016 report by the Government Accountability Office found that U.S. generic drug prices have been declining since 2010.
"To say that times are changing would be an understatement," Besch said.
The competitiveness of the market has been a flash point for generic drug-makers, as interim CEO Yitzhak Peterburg blamed his company's recent poor performance on saturation.
"[Teva] experienced … greater competition as a result of an increase in generic drug approvals by the U.S. FDA," Peterburg said in the earnings release. He added that "customer consolidation" hurt sales in the U.S., before saying competition hurt new product launches, some of which were delayed in the recent quarter.
Teva also missed top and bottom line estimates in its most recent earnings report.
Mylan's stock is down more than 17 percent this year while Teva's recent decline puts it about 51 percent lower over the same period.